First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

In a phase III randomized trial, we compared the effectiveness and tolerability of fadrozole (CGS 16949A), a non-steroidal aromatase inhibitor, to tamoxifen as first-line endocrine therapy in postmenopausal women with advanced breast cancer. Two hundred twelve eligible patients were randomized to re...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 1996-07, Vol.7 (5), p.471
Hauptverfasser:	Thürlimann, B, Beretta, K, Bacchi, M, Castiglione-Gertsch, M, Goldhirsch, A, Jungi, W F, Cavalli, F, Senn, H J, Fey, M, Löhnert, T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Disease-Free Survival Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Fadrozole - adverse effects Fadrozole - therapeutic use Female Humans Middle Aged Prognosis Prospective Studies Survival Rate Tamoxifen - adverse effects Tamoxifen - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!